Sight Sciences downgraded by Lake Street with a new price target
$SGHT
Medical/Dental Instruments
Health Care
Lake Street downgraded Sight Sciences from Buy to Hold and set a new price target of $5.00 from $10.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/6/2024 | $5.50 | Buy | UBS |
| 11/4/2024 | $10.00 → $5.00 | Buy → Hold | Lake Street |
| 8/21/2024 | $10.00 | Buy | Lake Street |
| 9/12/2023 | $10.00 → $4.50 | Neutral → Underperform | BofA Securities |
| 9/12/2023 | $15.00 → $5.50 | Overweight → Neutral | Piper Sandler |
| 9/12/2023 | Outperform → Mkt Perform | William Blair | |
| 8/24/2023 | $12.00 → $8.40 | Overweight → Equal-Weight | Morgan Stanley |
| 7/10/2023 | $15.00 → $9.00 | Buy → Neutral | Citigroup |
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con
MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023. "We are very excited to have Matt join Sight Sciences as we scale our Surgical Glaucoma and Dry Eye businesses. Matt is a highly talented medtech business leader with a track record of success in transforming treatment paradigms with disruptive new technology, and predictably scaling in a public high-growth
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov
10-K - Sight Sciences, Inc. (0001531177) (Filer)
8-K - Sight Sciences, Inc. (0001531177) (Filer)
8-K - Sight Sciences, Inc. (0001531177) (Filer)
SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G - Sight Sciences, Inc. (0001531177) (Subject)
UBS initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $5.50
Lake Street downgraded Sight Sciences from Buy to Hold and set a new price target of $5.00 from $10.00 previously
Lake Street initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $10.00
MENLO PARK, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the 24th Annual Needham Healthcare Conference being held virtually. Sight Sciences' management is scheduled to present on Tuesday, April 8, 2025, at 12:45 pm PT / 3:45 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the "Investors" section of the Company's website at https://investors.sightsciences.com/. About Sight Sc
MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the fourth quarter and full year ended December 31, 2024 and initiated financial guidance for full year 2025. Recent Financial Highlights Generated fourth quarter 2024 total revenue of $19.1 million, an increase of 2% compared to the same period in the prior year, and full year 2024 total revenue of $79.9 million, a decrease of 1% compared to full year 2023.Achieved total gross marg
A Meta-Analysis of 22 Studies, and Data from the IRIS® Registry Highlighting Clinical Outcomes in Real-World Clinical Practice, Demonstrates Significant, Long-Term IOP Reduction and Medication Reduction with the OMNI® Surgical System MENLO PARK, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients' lives, today announced that multiple presentations on the OMNI® Surgical System ("OMNI") will be presented at the 2025 American Glaucoma Society ("AGS") Annual Meeting in W
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the fourth quarter and full year ended December 31, 2024 and initiated financial guidance for full year 2025. Recent Financial Highlights Generated fourth quarter 2024 total revenue of $19.1 million, an increase of 2% compared to the same period in the prior year, and full year 2024 total revenue of $79.9 million, a decrease of 1% compared to full year 2023.Achieved total gross marg
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024, after the market close on Wednesday, March 5, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the even
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the third quarter ended September 30, 2024, and updated its adjusted operating expenses guidance for full year 2024. Third Quarter 2024 Financial and Business Highlights Generated total revenue of $20.2 million, an increase of 1% compared to the same period in the prior year.Generated positive cash flow of $0.4 million, a substantial improvement compared to $10.0 million cash used in
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)